The second outer ripple lands back where the story began — inside healthcare. As GLP-1s are studied and approved for more conditions, from sleep apnea to heart and kidney disease, they create a double-edged question for other companies: a fresh tailwind for some, a quiet threat to others. For the businesses making GLP-1 medical devices and the procedures these drugs touch, the effect can cut either way.
Part 7 of 8
Devices, surgery & care
4 Jun 2026GLP-1 ripple: healthcare winners and losers
How GLP-1s ripple through healthcare — diabetes devices, sleep apnea, bariatric surgery, dialysis — and which companies could win or lose.
Dual guardrail: this article is information only. It is not medical advice and not investment advice. Speak to a locally regulated professional before acting on anything you read.
Key Takeaways
- 1This article covers key developments in the crypto market
- 2Always verify claims with official FCA and regulatory sources
- 3Past performance does not guarantee future results
- 4Consider speaking to a qualified financial adviser before acting
- 5TradeRadarNews provides information only — not financial advice
The drugs do not stop at weight. As GLP-1s show benefits across other conditions, they reshape demand for devices, surgery, and care across healthcare.
Where this sits in the ripple
Duopoly · Pill · Factory · Delivery · Access · Consumer ripple · Healthcare ripple · Forces
This ring runs alongside the Consumer Ripple, both flowing from the makers' success. Links up to The Boom, and cross-links to the devices and providers links in our Healthcare series.
The win-or-lose question
The same drug can help one company and hurt another. The pieces below each carry a genuinely two-sided debate — which is exactly why they belong in a both-sides series.
DexCom (DXCM) and Insulet (PODD) — diabetes devices
What they do: DexCom makes continuous glucose monitors; Insulet makes insulin-delivery (pump) systems, both used widely in diabetes. The numbers:. The debate / edge: GLP-1s could grow their market (more diagnosed patients engaging with care) or shrink it (better-controlled or fewer progressing patients). The risk: genuine uncertainty over how widespread GLP-1 use changes long-term demand for diabetes hardware.
ResMed (RMD) — sleep apnea
What they do: makes devices (including CPAP machines) for sleep apnea, a condition linked to excess weight. The numbers:. The debate / edge: a GLP-1 (Zepbound) won a sleep-apnea indication, sharpening the question of whether weight loss reduces the need for CPAP — though ResMed argues the drugs surface more diagnosed patients, helping demand. The risk: the bear thesis that effective weight-loss drugs erode the long-term market for its core devices.
DaVita (DVA) — dialysis
What they do: runs a large US dialysis network for kidney-failure patients (profiled at home in the Healthcare providers link). The numbers:. The debate / edge: GLP-1s have shown kidney benefits, which over the long run could slow progression to kidney failure. The risk: that long-term effect on dialysis volumes is real but two-sided and slow to play out.
Context, not profiles. Bariatric-surgery providers face a similar two-sided question (do drugs replace surgery, or funnel more patients toward it?), and cardiovascular-device makers watch the heart-health data closely.
The bull and bear case
The bull case: every new approved use expands the drugs' value and can lift linked categories — more diagnosis, more engagement with care, more conditions addressed.
The bear case: for some device and procedure businesses, healthier patients mean less demand over time. The direction of the effect genuinely varies by company.
What feeds it, what it feeds
This ripple flows from the makers' expanding reach in The Duopoly and The Pill. One question now hangs over every ring we have mapped — is the boom durable? That is the final piece, The Forces. Back to the map: The Boom.
This article is for information only. It is not medical advice and not investment advice or a recommendation to buy or sell any security. TradeRadarNews is not a licensed financial or medical adviser. Figures are accurate as of June 2026 and will change. Markets carry risk, including loss of capital. Rules, taxes, and available products differ by country — do your own research and consult a locally regulated professional.
Risk Warning: Trading and investing carries significant risk. Your investments can fall as well as rise. CFDs carry high risk of rapid loss due to leverage. Cryptocurrency is not FCA-regulated and not covered by FSCS. This is information only, not financial advice. Seek independent advice before investing.
Written by
TradeRadarNews Team
Editorial Team
Our editorial team covers markets, fintech, and regulatory developments across the UK and globally.